...Thank you, Michelle, and thanks to all of you who are joining our CEO, Dr. Shai Gozani, and myself for today's Q3 earnings call. By way of background, we are a medtech company. Our mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health. Our commercial products are noninvasive. They address worldwide market opportunities. They have no direct competition. There are alternatives but not substitutes. Our neurodiagnostics are DPNCheck and ADVANCE, and our neurotherapeutics are the Quell product line. Our business model is razor-razorblade. Aftermarket revenue is the principal component of our product line profitability. Our strategic focus is to expand DPNCheck in the Medicare Advantage market and to develop the Quell portfolio for specific disease indications. Today, we reported Q3 revenue of $2 million and year-to-date revenue of $6.4 million. In both the quarterly and the year-to-date periods, revenue was essentially flat with...